Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

37.60
-0.9300-2.41%
Post-market: 37.38-0.2249-0.60%19:51 EDT
Volume:1.78M
Turnover:67.11M
Market Cap:4.00B
PE:45.85
High:38.44
Open:38.09
Low:37.15
Close:38.53
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.43
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:6.17
PE(LYR):45.85

Loading ...

Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients

Reuters
·
7 hours ago

Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff disposes of 26,198 common shares; value $1,312,000

Reuters
·
Yesterday

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

TIPRANKS
·
Mar 26

Piper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
Mar 26

Corcept Faces Investor Suit Over Relacorilant NDA Disclosure

TIPRANKS
·
Mar 26

Corcept Therapeutics Inc: Wholesale Acquisition Cost of a 28-Day Cycle of Lifyorli Therapy Is $37,900

THOMSON REUTERS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 26

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel for Treatment of Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Mar 26

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

TIPRANKS
·
Mar 26

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

TIPRANKS
·
Mar 26

Corcept Therapeutics rises 28.6%

TIPRANKS
·
Mar 26

What's Behind The Jump In Corcept Therapeutics Stock?

Benzinga
·
Mar 26

US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer

Reuters
·
Mar 25

Corcept Therapeutics Shares up 46.7% After FDA Approves Co's Drug to Treat Ovarian Cancer

THOMSON REUTERS
·
Mar 25

BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer

Reuters
·
Mar 25

FDA Approves Relacorilant With Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

THOMSON REUTERS
·
Mar 25

FDA approves Corcept Therapeutics’ Lifyorli for certain cancers

TIPRANKS
·
Mar 25

Corcept Therapeutics jump 10% after FDA approves Lifyorli cancer treatment

TIPRANKS
·
Mar 25

Corcept Therapeutics trading halted, volatility trading pause

TIPRANKS
·
Mar 25